|
End-of-day quote
Amman S.E.
2026-08-23
|
5-day change | 1st Jan Change | ||
| 1.840 JOD | 0.00% |
|
-7.07% | +15.00% |
| 07-21 | Philadelphia Pharmaceuticals Company Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-27 | Philadelphia Pharmaceuticals Q1 profit 255,632 dinars | RE |
Company Valuation: Philadelphia Pharmaceuticals Company
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 10.72 | 10.28 | 10.42 | 10.72 | 11.25 | 12 |
| Change | - | -4.2% | 1.46% | 2.88% | 4.9% | 6.67% |
| Enterprise Value (EV) 1 | 10.78 | 10.06 | 10.76 | 10.82 | 11.58 | 11.93 |
| Change | - | -6.6% | 6.87% | 0.56% | 7.09% | 3.01% |
| P/E | 75.7x | 25x | 14.9x | 13.3x | 13.7x | 11.9x |
| PBR | 0.94x | 0.85x | 0.84x | 0.84x | 0.86x | 0.89x |
| PEG | - | 0x | 0.2x | 0.9x | 7.72x | 0.5x |
| Capitalization / Revenue | 1.39x | 1.56x | 1.24x | 1.28x | 1.28x | 1.31x |
| EV / Revenue | 1.4x | 1.52x | 1.28x | 1.29x | 1.32x | 1.3x |
| EV / EBITDA | 14.4x | 11.4x | 8.83x | 6.56x | 6.93x | 6.71x |
| EV / EBIT | 23x | 14x | 9.79x | 7.98x | 8.29x | 7.76x |
| EV / FCF | 8.85x | -61.6x | -38.2x | 20.8x | 11.4x | 17.7x |
| FCF Yield | 11.3% | -1.62% | -2.62% | 4.8% | 8.76% | 5.64% |
| Dividend per Share 2 | - | 0.06 | 0.06 | 0.07 | 0.07 | - |
| Rate of return | - | 4.38% | 4.32% | 4.9% | 4.67% | - |
| EPS 2 | 0.0189 | 0.0547 | 0.0935 | 0.1076 | 0.1095 | 0.134 |
| Distribution rate | - | 110% | 64.2% | 65% | 63.9% | - |
| Net sales 1 | 7.697 | 6.601 | 8.415 | 8.405 | 8.762 | 9.169 |
| EBITDA 1 | 0.7481 | 0.8793 | 1.218 | 1.649 | 1.672 | 1.779 |
| EBIT 1 | 0.4689 | 0.7192 | 1.098 | 1.355 | 1.397 | 1.537 |
| Net income 1 | 0.1417 | 0.4102 | 0.7011 | 0.8072 | 0.8215 | 1.005 |
| Net Debt 1 | 0.0504 | -0.2103 | 0.3316 | 0.0922 | 0.3336 | -0.0677 |
| Reference price 2 | 1.430 | 1.370 | 1.390 | 1.430 | 1.500 | 1.600 |
| Nbr of stocks (in thousands) | 7,500 | 7,500 | 7,500 | 7,500 | 7,500 | 7,500 |
| Announcement Date | 6/7/21 | 3/3/22 | 3/16/23 | 2/11/24 | 2/6/25 | 3/29/26 |
1JOD in Million2JOD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 19.48M | |
| 35.1x | 6.58x | 22.81x | 0.9% | 47.71B | |
| 18.6x | 2.22x | 10.04x | 1.39% | 40.3B | |
| 27.88x | 3.39x | 17.57x | 0.91% | 12.09B | |
| 26.85x | 3.84x | 15.92x | 0.6% | 11.68B | |
| 18.73x | 3.33x | 11.58x | 3.85% | 9.19B | |
| 9.03x | 2.08x | 5.42x | 4.46% | 7.57B | |
| 15.95x | 2.08x | 6.76x | 3.2% | 7.24B | |
| 28.19x | 3.68x | 17.11x | 0.16% | 6.84B | |
| Average | 22.54x | 3.40x | 13.40x | 1.93% | 15.85B | |
| Weighted average by Cap. | 25.41x | 4.04x | 15.46x | 1.48% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PHIL Stock
- Valuation Philadelphia Pharmaceuticals Company
Select your edition
All financial news and data tailored to specific country editions
